Overview A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) Status: Recruiting Trial end date: 2023-07-15 Target enrollment: Participant gender: Summary This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP. Phase: Phase 2 Details Lead Sponsor: Transposon Therapeutics, Inc.